ReviewAnnals of surgical oncology2023
The Landmark Series-Addressing Disparities in Breast Cancer Screening: New Recommendations for Black Women.
Review in Annals of surgical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 27 citations in OpenAlex.
- ASO Education and Training: Taking the Next Step in Surgical Oncology Health Disparities Research: Identifying Root Causes and Targets for Actionable Change.Annals of surgical oncology · 2026Review
- Robotic vs. laparoscopic Ivor Lewis esophagectomy for esophageal cancer: a weighted short- and long-term outcomes analysis.Surgical endoscopy · 2026Article
- Annals of Surgical Oncology Landmark Series Disparities in Surgical Oncology: Breast Cancer.Annals of surgical oncology · 2025Review
- Associations between social drivers of health and breast cancer stage at diagnosis among U.S. Black women.NPJ breast cancer · 2025Article
- Factors influencing prophylactic surgical intervention in women with genetic predisposition for breast cancer.Journal of surgical oncology · 2024Article
- Breast Articles From 2023: Informing Practice Across the Continuum of Care.Annals of surgical oncology · 2024Review
- Racial Disparities in Breast Cancer: from Detection to Treatment.Current oncology reports · 2024Review
- Addressing Data Aggregation and Data Inequity in Race and Ethnicity Reporting and the Impact on Breast Cancer Disparities.Annals of surgical oncology · 2024Article
- Insufficient Reporting of Race and Ethnicity in Breast Cancer Clinical Trials.Annals of surgical oncology · 2023Review
Corrections and comments
- Commented on by
Authors and funding
7 authors at 7 institutions in 2 countries.
Funding
Abstract
Randomized, clinical trials have established the efficacy of screening mammography in improving survival from breast cancer for women through detection of early, asymptomatic disease. However, disparities in survival rates between black women and women from other racial and ethnic groups following breast cancer diagnosis persist. Various professional groups have different, somewhat conflicting, guidelines with regards to recommended age for commencing screening as well as recommended frequency of screening exams, but the trials upon which these recommendations are based were not specifically designed to examine benefit among black women. Furthermore, these recommendations do not appear to incorporate the unique epidemiological circumstances of breast cancer among black women, including higher rates of diagnosis before age 40 years and greater likelihood of advanced stage at diagnosis, into their formulation. In this review, we examined the epidemiologic and socioeconomic factors that are associated with breast cancer among black women and assess the implications of these factors for screening in this population. Specifically, we recommend that by no later than age 25 years, all black women should undergo baseline assessment for future risk of breast cancer utilizing a model that incorporates race (e.g., Breast Cancer Risk Assessment Tool [BCRAT], formerly the Gail model) and that this assessment should be conducted by a breast specialist or a healthcare provider (e.g., primary care physician or gynecologist) who is trained to assess breast cancer risk and is aware of the increased risks of early (i.e., premenopausal) and biologically aggressive (e.g., late-stage, triple-negative) breast cancer among black women.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.